-
1 Comment
Therapix Biosciences Ltd is currently in a long term uptrend where the price is trading 78.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Therapix Biosciences Ltd gets an overall score of 2/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | US88339A3023 |
| Market Cap | 4M |
|---|---|
| PE Ratio | None |
| Target Price | 18 |
| Dividend Yield | 0.0% |
| Beta | 0.39 |
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TRPX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
